# PDUFA outcomes: approvals and CRLs on past target dates

Canonical: https://sec-api.dev/pdufa-outcomes

> Of 114 past PDUFA target dates with a recorded outcome, 78 ended in approval and 36 in a complete response letter (68% approved).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### How often does the FDA approve a drug by its PDUFA date?

Of 114 past PDUFA target dates with a recorded outcome, 78 ended in approval and 36 in a complete response letter (68% approved). Most recent: ivonescimab (SMMT), complete response letter, target date November 14, 2026. [Calendar and source filings](https://sec-api.dev/pdufa-outcomes)

Source: SEC Form 10-K, accession 0001599298-26-000015, https://www.sec.gov/Archives/edgar/data/1599298/000159929826000015/smmt-20251231.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/pdufa-outcomes#answer

## Outcomes

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 14, 2026 | [Ivonescimab PDUFA date](https://sec-api.dev/pdufa/ivonescimab) | SMMT |  | completed, complete response letter | "In January 2026, the FDA accepted for filing our BLA seeking approval of ivonescimab in combination with chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-squamous NSCLC post-TKI therapy and provided a PDUFA target action date of November 14, 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000015/smmt-20251231.htm)) |
| October 26, 2026 | [HIBSAGO (bepirovirsen) PDUFA date](https://sec-api.dev/pdufa/bepirovirsen) | GSK |  | completed, approved | "In Q1, the US FDA accepted for priority review a New Drug Application (NDA) for bepirovirsen and set 26 October 2026 as the decision goal date." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426004051/a2755c.htm)) |
| October 24, 2026 | [Joenja® (leniolisib) PDUFA date](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed, approved | "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 24, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000033/a2026hy1pressrelease.htm)) |
| September 30, 2026 | [ISEMBYLD (apitegromab) PDUFA date](https://sec-api.dev/pdufa/apitegromab) | SRRK |  | completed, approved | "Apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA) review by FDA continues to advance with two fill-finish facilities, representing two independent paths to an FDA approval decision by September 30, 2026 Prescription Drug User Fee Act (PDUFA) date" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000119312526336715/srrk-ex99_1.htm)) |
| September 26, 2026 | [ATEBRIOZ® (zilurgisertib) PDUFA date](https://sec-api.dev/pdufa/zilurgisertib) | MIRM |  | completed, approved | "•Presented positive pivotal Phase 2 results from the PROGRESS study of zilurgisertib in fibrodysplasia ossificans progressiva (FOP) at ENDO 2026; Prescription Drug User Fee Act (PDUFA) target action date for the zilurgisertib NDA is September 26, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000044/mirm-20260805xexx991.htm)) |
| September 22, 2026 | [ZANVASTRO™ (zilganersen) PDUFA date](https://sec-api.dev/pdufa/zilganersen) | IONS |  | completed, approved | "The FDA has granted Priority Review of zilganersen, with a Prescription Drug User Fee Act, or PDUFA, action date of September 22, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/874015/000087401526000251/form10q.htm)) |
| August 25, 2026 | [Ziihera® (zanidatamab) PDUFA date](https://sec-api.dev/pdufa/zanidatamab) | JAZZ | with first-line | completed, approved | "•U.S. Food and Drug Administration (FDA) granted Priority Review and set Prescription Drug User Fee Act (PDUFA) target action date of August 25, 2026 for supplemental Biologics License Application (sBLA) for zanidatamab containing combinations in first-line (1L) gastroesophageal adenocarcinoma (GEA)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm)) |
| August 2, 2026 | [Opdivo® (nivolumab) PDUFA date](https://sec-api.dev/pdufa/nivolumab) | REPL |  | completed, approved | "On June 26, 2026 we announced the FDA accepted the BLA resubmission as a Class 1 resubmission with an action date of August 2, 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/repl-20260331.htm)) |
| Aug 2026 | [MIMRYLO™ (rusfertide) PDUFA date](https://sec-api.dev/pdufa/rusfertide) | PTGX |  | completed, approved | "As announced on March 2nd, the NDA for rusfertide was accepted by the FDA and granted Priority Review in Q1 2026, with a PDUFA goal date in August 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465926091099/tm2622272d1_ex99-1.htm)) |
| July 26, 2026 | [Furosemide PDUFA date](https://sec-api.dev/pdufa/furosemide) | MNKD |  | completed, approved | "FDA accepted for review a supplemental New Drug Application (sNDA) for Furoscix ReadyFlow Autoinjector; with a PDUFA target action date of July 26, 2026; if approved, it would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 seconds" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312526073509/mnkd-ex99_1.htm)) |
| July 17, 2026 | [Revtorpyk (gedatolisib) PDUFA date](https://sec-api.dev/pdufa/gedatolisib) | FTH |  | completed, approved | "In particular, Celcuity has now reported positive topline Phase 3 results from both the PIK3CA wild-type cohort and the PIK3CA mutant cohort of its VIKTORIA-1 trial, has its New Drug Application for gedatolisib in HR+/HER2-, PIK3CA wild-type metastatic breast cancer under FDA Priority Review with a Prescription Drug User Fee Act goal date of July 17, 2026, and has announced its intention to file a supplemental New Drug Application for the PIK3CA mutant indication." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1829802/000119312526225333/snse-20260331.htm)) |
| July 11, 2026 | [TAXOL® (paclitaxel) PDUFA date](https://sec-api.dev/pdufa/paclitaxel) | CORT | with platinum-resistant ovarian cancer | completed, approved | "•New Drug Application - FDA reviewing NDA for relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer, with a July 11, 2026 PDUFA date" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828026011080/cort022426ex991pressrelease.htm)) |
| Q3 2026 | [LISRAYA™ (brepocitinib) PDUFA date](https://sec-api.dev/pdufa/brepocitinib) | ROIV |  | completed, approved | "Brepocitinib Dermatomyositis Priovant Small Molecule PDUFA Date 3Q 2026" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000090/roiv-20260630.htm)) |
| Q3 2026 | [ORZEYFUL (oveporexton) PDUFA date](https://sec-api.dev/pdufa/oveporexton) | TAK |  | completed, approved | "The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of calendar year 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000162/noticeofconvocationofthe.htm)) |
| Q3 2026 | [MIMRYLO™ (rusfertide) PDUFA date](https://sec-api.dev/pdufa/rusfertide) | TAK |  | completed, approved | "The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000162/noticeofconvocationofthe.htm)) |
| June 30, 2026 | [TRYNGOLZA (olezarsen) PDUFA date](https://sec-api.dev/pdufa/olezarsen) | IONS | severe hypertriglyceridemia, or sHTG, with an action date of June 30, 2026 | completed, approved | "Olezarsen on track to launch this year as a transformational medicine for severe hypertriglyceridemia (sHTG), assuming approval o sNDA accepted by the FDA for Priority Review for the treatment of sHTG with a Prescription Drug User Fee Act (PDUFA) target action date of June 30, 2026 o" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/874015/000114036126017637/ef20071749_ex99-1.htm)) |
| June 30, 2026 | [Lumvoa™ (veligrotug) PDUFA date](https://sec-api.dev/pdufa/veligrotug) | VRDN |  | completed, approved | "- PDUFA target action date of June 30, 2026 for veligrotug in thyroid eye disease (TED); organization is launch-ready -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526205010/d149508dex991.htm)) |
| June 29, 2026 | [ZORYVE (roflumilast) PDUFA date](https://sec-api.dev/pdufa/roflumilast) | ARQT | plaque psoriasis in children down | completed, approved | "•sNDA accepted for ZORYVE cream 0.3% for the treatment of plaque psoriasis down to 2 years of age with a Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730626000017/pressreleaseex991q42025.htm)) |
| June 26, 2026 | [Lumvoa™ (veligrotug) PDUFA date](https://sec-api.dev/pdufa/veligrotug) | VRDN |  | completed, approved | "- Lumvoa (veligrotug-vvze) approved by the FDA for thyroid eye disease (TED) on June 26, 2026, ahead of target PDUFA date and immediately launched in the U.S. -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526336691/d174744dex991.htm)) |
| June 19, 2026 | [WELIREG® (belzutifan) PDUFA date](https://sec-api.dev/pdufa/belzutifan) | MRK |  | completed, approved | "Patients With Earlier-Stage RCC; Results From Phase 3 LITESPARK-022 Trial; FDA Set PDUFA Date of June 19, 2026 for WELIREG in combination with KEYTRUDA or KEYTRUDA QLEX" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/tm2612241d1_ex99-1.htm)) |
| June 18, 2026 | [Tebipenem PDUFA date](https://sec-api.dev/pdufa/tebipenem) | SPRO |  | completed, approved | "New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312526221567/d147628dex991.htm)) |
| June 5, 2026 | [IBRANCE® (palbociclib) PDUFA date](https://sec-api.dev/pdufa/palbociclib) | ARVN |  | completed, approved | "•Footnotes included in the graphic above: (a) Includes relapsed/refractory angioimmunoblastic T-cell lymphoma, or AITL, and relapsed/refractory mature B cell NHL; (b) PDUFA date of June 5, 2026; and (c) Phase 1/2 combination clinical trials with palbociclib, atirmociclib, abemaciclib, ribociclib, samuraciclib, everolimus." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1655759/000162828026011226/arvn-20251231.htm)) |
| June 5, 2026 | [VEPPANU (vepdegestrant) PDUFA date](https://sec-api.dev/pdufa/vepdegestrant) | ARVN | with estrogen receptor-positive | completed, approved | "Vepdegestrant was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) and has been assigned a Prescription Drug User Fee Act (PDUFA) action date of June 5, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000165575925000147/arvnstrategicupdaterelea.htm)) |
| May 31, 2026 | [Indegene PDUFA date](https://sec-api.dev/pdufa/indegene) | CING |  | completed, complete response letter | "2025, the FDA accepted for review the NDA for CTx-1301 and assigned a PDUFA target action date of May 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000149315226051841/ex99-1.htm)) |
| May 29, 2026 | [Afrezza (afrezza) PDUFA date](https://sec-api.dev/pdufa/afrezza) | MNKD |  | completed, approved | "o sBLA for Afrezza® in pediatric population accepted for FDA review; PDUFA date of May 29, 2026 o" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312525265810/mnkd-ex99_1.htm)) |
| April 30, 2026 | [AUVELITY (dextromethorphan-bupropion) PDUFA date](https://sec-api.dev/pdufa/dextromethorphan-bupropion) | AXSM |  | completed, approved | "AXS-05 for Alzheimer's disease agitation, PDUFA target action (April 30, 2026)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526062421/axsm-ex99_1.htm)) |
| April 28, 2026 | [IDVYNSO (doravirine-islatravir) PDUFA date](https://sec-api.dev/pdufa/doravirine-islatravir) | MRK |  | completed, approved | "The FDA set a PDUFA, or target action, date of April 28, 2026 for the new drug application, which is based on findings of the Phase 3 MK-8591A-051 and MK-8591A-052 clinical trials." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm)) |
| April 23, 2026 | [GTX-104 PDUFA date](https://sec-api.dev/pdufa/gtx-104) | GRCE | aSAH | completed, complete response letter | "FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036126004927/ef20064916_ex99-1.htm)) |
| April 13, 2026 | [FILSPARI (sparsentan) PDUFA date](https://sec-api.dev/pdufa/sparsentan) | TVTX |  | completed, approved | "PDUFA target action date for FILSPARI in FSGS is April 13, 2026; Company positioned for a successful commercial launch, if approved" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000013/aex991_2025q4x10xkearnings.htm)) |
| April 10, 2026 | [Opdivo® (nivolumab) PDUFA date](https://sec-api.dev/pdufa/nivolumab) | REPL | advanced melanoma | completed, complete response letter | "The PDUFA date set by the FDA is April 10, 2026 based on a Class II resubmission timeline." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1737953/000110465925100605/tm2529069d1_8k.htm)) |
| April 10, 2026 | [Vusolimogene oderparepvec PDUFA date](https://sec-api.dev/pdufa/vusolimogene-oderparepvec) | REPL |  | completed, complete response letter | "Act (PDUFA) target action date of April 10, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465926009510/tm264822d1_ex99-1.htm)) |
| April 5, 2026 | [Tividenofusp alfa PDUFA date](https://sec-api.dev/pdufa/tividenofusp-alfa) | DNLI |  | completed, approved | "•Tividenofusp alfa (DNL310; ETV:IDS) launch readiness established ahead of April 5, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Hunter syndrome" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000020/ex991pressreleaseq42025.htm)) |
| April 3, 2026 | [SPINRAZA (nusinersen) PDUFA date](https://sec-api.dev/pdufa/nusinersen) | BIIB |  | completed, approved | "•Today announced that high dose nusinersen (SPINRAZA) in SMA was successfully resubmitted with the FDA with an updated PDUFA date of April 3, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504525000047/exhibit991-q32025pressrele.htm)) |
| March 31, 2026 | [ZYCUBO (CUTX-101) PDUFA date](https://sec-api.dev/pdufa/cutx-101) | FBIO |  | completed, approved | "As of December 31, 2025, although the NDA for CUTX-101 had been resubmitted and assigned a new PDUFA date of January 14, 2026, following the October 2024 Complete Response Letter, significant uncertainty remained regarding whether approval would be obtained, whether a PRV would be issued, and whether a PPS PRV Sale could be executed on a timely basis on agreeable terms prior to the March 31, 2026 mandatory exchange date." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1429260/000110465926126531/fbio-20260930x10q.htm)) |
| March 28, 2026 | [KRESLADI (marnetegragene autotemcel) PDUFA date](https://sec-api.dev/pdufa/marnetegragene-autotemcel) | RCKT |  | completed, approved | "KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA date" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1281895/000114036126006981/ef20066645_ex99-1.htm)) |
| March 20, 2026 | [IMCIVREE® (setmelanotide) PDUFA date](https://sec-api.dev/pdufa/setmelanotide) | RYTM | acquired hypothalamic obesity | completed, approved | "-- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity --" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000110465926021801/tm267699d1_ex99-1.htm)) |
| March 16, 2026 | [Reproxalap PDUFA date](https://sec-api.dev/pdufa/reproxalap) | ALDX |  | completed, complete response letter | "On December 15, 2025, Aldeyra announced that the FDA had requested submission of the clinical study report for the field trial, triggering an extension of the PDUFA date to March 16, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-20260317.htm)) |
| March 10, 2026 | [Deramiocel PDUFA date](https://sec-api.dev/pdufa/deramiocel) | CAPR |  | completed, complete response letter | "Press Release, titled "Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA", dated March 10, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1133869/000110465926025657/capr-20260310x8k.htm)) |
| February 28, 2026 | [Dupixent (dupilumab) PDUFA date](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "Dupixent sBLA accepted for priority review by the US FDA with a target action date of February 28, 2026; if approved, Dupixent would be the first and only medicine indicated specifically for AFRS, which would be its ninth FDA-approved indication" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312525285701/d895566dex991.htm)) |
| February 25, 2026 | [DESMODA (desmopressin) PDUFA date](https://sec-api.dev/pdufa/desmopressin) | ETON |  | completed, approved | "On July 8, 2025, Eton Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the Company's New Drug Application for ET-600, a proprietary patented formulation of desmopressin oral solution, was accepted for review by the Food and Drug Administration (FDA) and assigned a Prescription Drug User Fee Administration target action date of February 25, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1710340/000143774925022298/eton20250702_8k.htm)) |
| February 21, 2026 | [BYSANTITM (milsaperidone) PDUFA date](https://sec-api.dev/pdufa/milsaperidone) | VNDA |  | completed, approved | "•BysantiTM (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007256/vnda8-k2112026exhibit991.htm)) |
| February 8, 2026 | [Clemidsogene lanparvovec PDUFA date](https://sec-api.dev/pdufa/clemidsogene-lanparvovec) | RGNX |  | completed, complete response letter | "Clemidsogene lanparvovec (RGX-121) on track to be first gene therapy and one-time treatment for MPS II; PDUFA date February 8, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312525268101/rgnx-ex99_1.htm)) |
| January 31, 2026 | [Joenja® (leniolisib) PDUFA date](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed, complete response letter | "On October 1, 2025, we announced that the FDA had accepted the sNDA and granted Priority Review of the application and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831625000049/a2025q3pressrelease.htm)) |
| January 31, 2026 | [Anaphylm™ (dibutepinephrine) PDUFA date](https://sec-api.dev/pdufa/dibutepinephrine) | AQST | Type 1 allergic reactions | completed, complete response letter | "Anaphylm™ (dibutepinephrine) Sublingual Film The Company is in contact with the U.S. Food and Drug Administration (FDA) to gather further information about the deficiencies presently identified by the FDA in the New Drug Application (NDA) for Anaphylm, with the goal of addressing those deficiencies prior to the scheduled PDUFA action date of January 31, 2026, once disclosed to the Company." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000003/aquestivepressrelease-fi.htm)) |
| January 14, 2026 | [ZYCUBO (CUTX-101) PDUFA date](https://sec-api.dev/pdufa/cutx-101) | FBIO |  | completed, approved | "In December 2025, we announced the FDA accepted the resubmission of the NDA for CUTX-101 as a Class 1 resubmission with a new PDUFA target action date of January 14, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1429260/000110465926061233/fbio-20260331x10q.htm)) |
| January 10, 2026 | [Tab-cel (tabelecleucel) PDUFA date](https://sec-api.dev/pdufa/tabelecleucel) | ATRA |  | completed, complete response letter | "Tab-cel Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000119312525276209/d66575dex991.htm)) |
| December 31, 2025 | [MVASI® (bevacizumab) PDUFA date](https://sec-api.dev/pdufa/bevacizumab) | OTLK | wet AMD | completed, complete response letter | "Food and Drug Administration (FDA) PDUFA goal date for ONS-5010 is December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465925122786/tm2533934d1_ex99-1.htm)) |
| December 30, 2025 | [Corcept PDUFA date](https://sec-api.dev/pdufa/corcept) | CORT |  | completed, complete response letter | "FDA assigns a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000119312525044123/d914293dex991.htm)) |
| December 30, 2025 | [NEREUSTM (tradipitant) PDUFA date](https://sec-api.dev/pdufa/tradipitant) | VNDA | motion sickness | completed, approved | "Separately, the ongoing review of the pending, fully completed New Drug Application for tradipitant for the prevention of vomiting induced by motion remains on track, with a PDUFA target action date of December 30, 2025, positioning tradipitant as potentially the first new pharmacologic treatment for motion sickness in over 40 years." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828025055393/vnda8-k1242025exhibit991.htm)) |
| December 28, 2025 | [Tolebrutinib PDUFA date](https://sec-api.dev/pdufa/tolebrutinib) | SNY |  | completed, complete response letter | "On December 15, 2025, Sanofi provided an update on the ongoing review which stated that: (i) FDA was expecting the review to go beyond the previously communicated revised US target action date of December 28, 2025; (ii) further guidance from the FDA was expected by the end of the first quarter of 2026; and (iii) in response to an FDA request, Sanofi had submitted an expanded access protocol for tolebrutinib in nrSPMS." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312525332163/d65502dex991.htm)) |
| December 26, 2025 | [MYQORZO® (aficamten) PDUFA date](https://sec-api.dev/pdufa/aficamten) | CYTK | with obstructive hypertrophic cardiomyopathy | completed, approved | "Interactions with FDA Progressing Towards December 26, 2025 PDUFA Date for Aficamten; U.S. Commercial Launch Preparations on Track" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000119312525266842/cytk-ex99_1.htm)) |
| December 26, 2025 | [YARTEMLEA® (narsoplimab) PDUFA date](https://sec-api.dev/pdufa/narsoplimab) | OMER |  | completed, approved | "Following a comprehensive response to an FDA information request, the Agency extended the PDUFA date to December 26, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774925034824/ex_856792.htm)) |
| December 13, 2025 | [CARDAMYST (etripamil) PDUFA date](https://sec-api.dev/pdufa/etripamil) | MIST |  | completed, approved | "FDA Accepted the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465925076468/tm2523169d1_ex99-1.htm)) |
| December 12, 2025 | [ORLADEYO® (berotralstat) PDUFA date](https://sec-api.dev/pdufa/berotralstat) | BCRX | HAE aged 2 to 11 | completed, approved | "The Prescription Drug User Fee Act goal date for the company's new drug application for ORLADEYO granules in children with HAE aged 2 to <12 is December 12, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184325006881/exh_991.htm)) |
| November 30, 2025 | [TEPKINLY (epcoritamab) PDUFA date](https://sec-api.dev/pdufa/epcoritamab) | GMAB |  | completed, approved | "•U.S. FDA has accepted for priority review new supplemental Biologics License Application (sBLA) for epcoritamab plus R2, with action date of November 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434265/000143426525000061/gmab_20250807xex99d1.htm)) |
| November 30, 2025 | [KOMZIFTI (ziftomenib) PDUFA date](https://sec-api.dev/pdufa/ziftomenib) | KURA | relapsed or refractory NPM1-m AML | completed, approved | "Continued regulatory interactions with the FDA ahead of the November 30, 2025 PDUFA target action date for ziftomenib as a monotherapy for adult patients with relapsed or refractory NPM1-m AML." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000119312525263491/kura-ex99_1.htm)) |
| November 18, 2025 | [REDEMPLO (plozasiran) PDUFA date](https://sec-api.dev/pdufa/plozasiran) | ARWR |  | completed, approved | "Arrowhead submitted a New Drug Application for approval of plozasiran in November 2024, and FDA has set a Prescription Drug User Fee Act ("PDUFA") action date of November 18, 2025—the target deadline by which FDA may make a decision on whether to approve plozasiran." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879407/000087940725000007/a9912025-09x10arrowheadc.htm)) |
| October 25, 2025 | [Revuforj® (revumenib) PDUFA date](https://sec-api.dev/pdufa/revumenib) | SNDX |  | completed, approved | "PDUFA target action date of October 25, 2025 IC, intensive chemotherapy" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000095017025101974/sndx-ex99_2.htm)) |
| October 13, 2025 | [ZORYVE (roflumilast) PDUFA date](https://sec-api.dev/pdufa/roflumilast) | ARQT | atopic dermatitis in children ages 2 to 5 with an | completed, approved | "•The Company has been assigned a Prescription Drug User Fee Act (PDUFA) action date of October 13, 2025 for the supplemental New Drug Application (sNDA) for ZORYVE cream 0.05% for the treatment of atopic dermatitis in children ages 2 to 5 years old." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730625000122/pressreleaseex991q22025.htm)) |
| Q4 2025 | [Levosimendan PDUFA date](https://sec-api.dev/pdufa/levosimendan) | TNXP |  | completed, approved | "FDA PDUFA goal date and anticipated fourth quarter 2025 launch of TNX-102 SL for fibromyalgia; $98.8 million in cash as of December" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1430306/000199937125002787/ex99-1.htm)) |
| September 30, 2025 | [ZYCUBO (CUTX-101) PDUFA date](https://sec-api.dev/pdufa/cutx-101) | FBIO | Menkes disease | completed, complete response letter | "FDA accepted New Drug Application filing for priority review of CUTX-101 to treat Menkes disease; PDUFA goal date of September 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000155837025011561/fbio-20250814xex99.htm)) |
| September 22, 2025 | [ISEMBYLD (apitegromab) PDUFA date](https://sec-api.dev/pdufa/apitegromab) | SRRK | Spinal Muscular Atrophy | completed, complete response letter | "Exhibit 99.1 target action date for apitegromab of September 22, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000155837025010399/srrk-20250806xex99d1.htm)) |
| September 22, 2025 | [SPINRAZA (nusinersen) PDUFA date](https://sec-api.dev/pdufa/nusinersen) | BIIB |  | completed, complete response letter | "•Nusinersen (SPINRAZA) higher dose regimen for SMA filings accepted by FDA and EMA; FDA PDUFA of September 22, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504525000004/exhibit991-q42024pressrele.htm)) |
| September 19, 2025 | [JAKAFI (ruxolitinib) PDUFA date](https://sec-api.dev/pdufa/ruxolitinib) | INCY |  | completed, approved | "The Prescription Drug User Fee Act (PDUFA) action date was extended by three months to September 19, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916925000100/incy-q22025xexx991.htm)) |
| late 2025 | [Oxylanthanum PDUFA date](https://sec-api.dev/pdufa/oxylanthanum) | UNCY |  | completed, complete response letter | "- Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoing commercial planning in preparation for anticipated commercial launch in late 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390025042967/ea024208101ex99-1_unicycive.htm)) |
| August 31, 2025 | [Deramiocel PDUFA date](https://sec-api.dev/pdufa/deramiocel) | CAPR | Duchenne muscular dystrophy | completed, complete response letter | "Biologics License Application (BLA) for deramiocel in the treatment of Duchenne muscular dystrophy (DMD) remains under priority review by the U.S. FDA, with a target Prescription Drug User Fee Act (PDUFA) date slated for August 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000155837025007574/capr-20250513xex99d1.htm)) |
| August 29, 2025 | [Wayrilz (rilzabrutinib) PDUFA date](https://sec-api.dev/pdufa/rilzabrutinib) | SNY |  | completed, approved | "Rilzabrutinib is currently under regulatory review in the US and the EU, with a US Food and Drug Administration target action date of August 29, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312524278124/d913939dex992.htm)) |
| August 28, 2025 | [FILSPARI (sparsentan) PDUFA date](https://sec-api.dev/pdufa/sparsentan) | TVTX |  | completed, approved | "•The FDA assigned a PDUFA target action date of August 28, 2025, to the Company's supplemental New Drug Application (sNDA) requesting modification of liver monitoring for FILSPARI in IgAN." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853325000008/aex991_2024q4x10xkearnings.htm)) |
| August 27, 2025 | [MVASI® (bevacizumab) PDUFA date](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | completed, complete response letter | "U.S. Food and Drug Administration (FDA) PDUFA goal date for ONS-5010 is August 27, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465925078622/tm2523462d1_ex99-1.htm)) |
| August 27, 2025 | [Zopapogene imadenovec PDUFA date](https://sec-api.dev/pdufa/zopapogene-imadenovec) | PGEN |  | completed, approved | "The United States Food and Drug Administration ("FDA") granted priority review to a Biologics License Application ("BLA") for PRGN-2012 with a Prescription Drug User Fee Act ("PDUFA") target action date set for August 27, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1356090/000135609025000024/pgen-20250630.htm)) |
| August 21, 2025 | [DAWNZERA™ (donidalorsen) PDUFA date](https://sec-api.dev/pdufa/donidalorsen) | IONS |  | completed, approved | "Donidalorsen on track to launch this year, assuming approval, with a U.S. PDUFA date of August 21, 2025 o" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/874015/000114036125027949/ef20052929_ex99-1.htm)) |
| August 19, 2025 | [Vatiquinone PDUFA date](https://sec-api.dev/pdufa/vatiquinone) | PTCT |  | completed, complete response letter | "In February 2025, the FDA accepted for filing the NDA and granted priority review with a target regulatory action date of August 19, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1070081/000155837025010796/tmb-20250630x10q.htm)) |
| August 18, 2025 | [FAYUVI (rebisufligene etisparvovec) PDUFA date](https://sec-api.dev/pdufa/rebisufligene-etisparvovec) | RARE |  | completed, complete response letter | "UX111, an investigational treatment for Sanfilippo syndrome, biologics license application (BLA) on track for PDUFA action date of August 18, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000095017025064473/rare-ex99_1.htm)) |
| August 15, 2025 | [Levosimendan PDUFA date](https://sec-api.dev/pdufa/levosimendan) | TNXP |  | completed, approved | "FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for fibromyalgia: if approved by FDA, TNX-102 SL would be the first new drug for fibromyalgia in more than 16 years" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1430306/000199937125011053/ex99-01.htm)) |
| August 12, 2025 | [BRINSUPRI® (brensocatib) PDUFA date](https://sec-api.dev/pdufa/brensocatib) | INSM | Bronchiectasis Remains | completed, approved | "The FDA had previously granted Priority Review to Insmed's NDA for brensocatib and set a target action date of August 12, 2025, under the Prescription" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125005570/ef20044166_ex99-1.htm)) |
| August 8, 2025 | [LNZ100 PDUFA date](https://sec-api.dev/pdufa/lnz100) | LENZ | presbyopia | completed, approved | "New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577625000054/a991q225pressrelease.htm)) |
| Aug 2025 | [Eylea® (eylea) PDUFA date](https://sec-api.dev/pdufa/eylea) | REGN | macular edema | completed, complete response letter | "•The Company now expects regulatory approvals to be delayed for its currently pending FDA applications for EYLEA HD (pre-filled syringe, every-four-week dosing, and for the treatment of macular edema following retinal vein occlusion), which have PDUFA dates in August 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/exhibit991q22025.htm)) |
| July 30, 2025 | [Ordspono™ (odronextamab) PDUFA date](https://sec-api.dev/pdufa/odronextamab) | REGN |  | completed, complete response letter | "•The FDA accepted for review the resubmission of the BLA for odronextamab, a bispecific antibody targeting CD20 and CD3, in relapsed/refractory (R/R) follicular lymphoma, with a target action date of July 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm)) |
| July 29, 2025 | [Sephience™ (sepiapterin) PDUFA date](https://sec-api.dev/pdufa/sepiapterin) | PTCT |  | completed, approved | "- Positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025, NDA review remains on track for July 29, 2025 PDUFA date -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000107008125000018/tmb-20250506xex99d1.htm)) |
| July 22, 2025 | [Opdivo® (nivolumab) PDUFA date](https://sec-api.dev/pdufa/nivolumab) | REPL |  | completed, complete response letter | "Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for priority review with a PDUFA date of July 22, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465925011851/tm256243d1_ex99-1.htm)) |
| June 30, 2025 | [AVMAPKI (avutometinib) PDUFA date](https://sec-api.dev/pdufa/avutometinib) | VSTM |  | completed, approved | "Avutometinib and Defactinib in Recurrent Low - Grade Serous Ovarian Cancer (LGSOC) PDUFA Action Date: June 30, 2025 Potential Launch in KRAS mutant Recurrent LGSOC in mid - 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1526119/000110465925026130/tm259913d1_ex99-1.htm)) |
| June 28, 2025 | [Oxylanthanum PDUFA date](https://sec-api.dev/pdufa/oxylanthanum) | UNCY |  | completed, complete response letter | "- Oxylanthanum carbonate (OLC) New Drug Application for hyperphosphatemia in chronic kidney disease patients on dialysis under review by the FDA with a PDUFA target action date of June 28, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390025026270/ea023632401ex99-1_unicycive.htm)) |
| June 23, 2025 | [IBTROZI (taletrectinib) PDUFA date](https://sec-api.dev/pdufa/taletrectinib) | NUVB | advanced ROS1+ NSCLC | completed, approved | "The PDUFA goal date of June 23, 2025 positions Nuvation Bio to commercialize taletrectinib in the U.S., if approved, in mid-2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312525114908/d905090dex991.htm)) |
| June 20, 2025 | [Dupixent (dupilumab) PDUFA date](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "In February 2025, the FDA accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent in bullous pemphigoid, with a target action date of June 20, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm)) |
| June 19, 2025 | [Yeztugo® (lenacapavir) PDUFA date](https://sec-api.dev/pdufa/lenacapavir) | GILD |  | completed, approved | "•Announced FDA accepted New Drug Application submissions for twice-yearly lenacapavir for HIV prevention under priority review, with a PDUFA date of June 19, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209525000009/exhibit991earningspressrel.htm)) |
| June 13, 2025 | [ZUSDURI (mitomycin) PDUFA date](https://sec-api.dev/pdufa/mitomycin) | URGN |  | completed, approved | "New Drug Application for UGN-102 on track for FDA-PDUFA target action date of June 13, 2025; assuming approval, commercial launch to immediately follow with product availability in July" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774925015955/ex_815371.htm)) |
| May 24, 2025 | [YUTREPIA (treprostinil) PDUFA date](https://sec-api.dev/pdufa/treprostinil) | LQDA |  | completed, approved | "Does not impact FDA's ability to take final action on NDA for YUTREPIA on PDUFA goal date of May 24, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465925046935/tm2514743d1_ex99-1.htm)) |
| May 22, 2025 | [ZORYVE (roflumilast) PDUFA date](https://sec-api.dev/pdufa/roflumilast) | ARQT |  | completed, approved | "•The Company submitted an sNDA for ZORYVE foam for scalp and body psoriasis to the FDA based on the positive results from the pivotal ARRECTOR Phase 3 trial and a Phase 2b trial, and has been assigned a PDUFA action date of May 22, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730625000091/pressreleaseex991q12025.htm)) |
| April 29, 2025 | [Prademagene PDUFA date](https://sec-api.dev/pdufa/prademagene) | ABEO |  | completed, approved | "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315224044514/ex99-1.htm)) |
| April 26, 2025 | [TLX101 PDUFA date](https://sec-api.dev/pdufa/tlx101) | TLX |  | completed, complete response letter | "The NDA for TLX101-CDx (Pixclara®15, 18F-floretyrosine or 18F-FET), Telix's brain cancer imaging candidate, continues to progress with a PDUFA goal date of 26 April 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000200719125000047/q1bizupdate.htm)) |
| April 20, 2025 | [Eylea® (eylea) PDUFA date](https://sec-api.dev/pdufa/eylea) | REGN |  | completed, complete response letter | "Longer term data in wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) are under FDA review with a PDUFA date of April 20, 2025 to potentially extend dosing intervals for EYLEA HD up to every-24 weeks." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-1.htm)) |
| April 18, 2025 | [Dupixent (dupilumab) PDUFA date](https://sec-api.dev/pdufa/dupilumab) | REGN | and adolescents aged 12 years and older with chronic spontaneous urticaria | completed, approved | "•The FDA accepted for review the resubmission of an sBLA for Dupixent to treat adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment, with a target action date of April 18, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/exhibit991q42024.htm)) |
| April 10, 2025 | [VYVGART (efgartigimod) PDUFA date](https://sec-api.dev/pdufa/efgartigimod) | ARGX |  | completed, approved | "This vision has already started to take shape as we continue to innovate on the patient experience with our pre- filled syringe (VYVGART SC) (with an expected Prescription Drug User Fee Act target action date (PDUFA Date) of April 10, 2025) and the auto-injector approval expected in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm)) |
| April 3, 2025 | [CABOMETYX® (cabozantinib) PDUFA date](https://sec-api.dev/pdufa/cabozantinib) | EXEL | with previously treated advanced NET | completed, approved | "In January 2025, Exelixis announced its key priorities and anticipated milestones for 2025, including: the potential commercial launch of CABOMETYX for the treatment of patients with previously treated advanced NET following completion of the FDA's review of Exelixis' sNDA, which has a PDUFA action date of April 3, 2025; expansion of zanzalintinib's pivotal development program with six ongoing or planned pivotal trials, including two pivotal RCC studies with Merck and additional" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976725000017/exel2024q42024exhibit991.htm)) |
| April 2, 2025 | [Reproxalap PDUFA date](https://sec-api.dev/pdufa/reproxalap) | ALDX | signs and symptoms of dry eye disease | completed, complete response letter | "Release") to announce the Extension Letter and that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's resubmitted New Drug Application (NDA) for reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease, and has assigned a Prescription Drug User Fee Act (PDUFA) date of April 2, 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000121390024099333/ea0221568-8k_aldeyra.htm)) |
| March 28, 2025 | [CTEXLI® (chenodiol) PDUFA date](https://sec-api.dev/pdufa/chenodiol) | MIRM |  | completed, approved | "•FDA Prescription Drug User Fee Act (PDUFA) date for chenodiol in cerebrotendinous xanthomatosis (CTX) is March 28, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942525000003/mirm-20250113xexx991.htm)) |
| March 27, 2025 | [CARDAMYST (etripamil) PDUFA date](https://sec-api.dev/pdufa/etripamil) | MIST |  | completed, complete response letter | "FDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465925023218/tm259067d1_ex99-1.htm)) |
| March 24, 2025 | [TLX007 PDUFA date](https://sec-api.dev/pdufa/tlx007) | TLX |  | completed, approved | "In July 2024, the FDA accepted the NDA for TLX007-CDx and assigned a PDUFA goal date of March 24, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/2007191/000114036125005562/ef20038762_20f.htm)) |
| March 23, 2025 | [AMVUTTRA® (vutrisiran) PDUFA date](https://sec-api.dev/pdufa/vutrisiran) | ALNY | with ATTR amyloidosis with cardiomyopathy | completed, approved | "** Guidance assumes FDA approval of the sNDA for vutrisiran for the treatment of adults with ATTR amyloidosis with cardiomyopathy by the March 23, 2025 PDUFA target action date." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000008/alny2025q1exhibit991.htm)) |
| January 15, 2025 | [Tab-cel (tabelecleucel) PDUFA date](https://sec-api.dev/pdufa/tabelecleucel) | ATRA |  | completed, complete response letter | "Tab-cel® U.S. BLA On-Track With PDUFA Target Action Date of January 15, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000095017024125334/atra-ex99_1.htm)) |
| January 7, 2025 | [Ryoncil (ryoncil) PDUFA date](https://sec-api.dev/pdufa/ryoncil) | MESO |  | completed, approved | "19 m e s o b l a s t Mesoblast resubmitted its Biologics License Application (BLA) to FDA for approval of RYONCIL on July 8, 2024 and anticipates a decision prior to or on the FDA's Prescription Drug User Fee Act (PDUFA) goal date of January 7, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509924000079/exhibit993-agm2024presen.htm)) |
| December 28, 2024 | [UNLOXCYT (cosibelimab) PDUFA date](https://sec-api.dev/pdufa/cosibelimab) | FBIO | metastatic or locally advanced cutaneous squamous cell carcinoma | completed, approved | "We could achieve up to two more U.S. FDA approvals in the next nine months, and our next anticipated PDUFA goal date is December 28, 2024, for cosibelimab, an anti-PD-L1 antibody, for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma ("cSCC")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000155837024015726/fbio-20241114xex99.htm)) |
| December 26, 2024 | [Revuforj® (revumenib) PDUFA date](https://sec-api.dev/pdufa/revumenib) | SNDX |  | completed, approved | "Positive data from the KMT2Ar AML and ALL patients in the trial supported a New Drug Application (NDA) filing for revumenib in R/R KMT2Ar acute leukemia, which is currently under review by the U.S. FDA with a PDUFA action date of December 26, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000095017024124545/sndx-ex99_1.htm)) |
| November 29, 2024 | [Attruby (acoramidis) PDUFA date](https://sec-api.dev/pdufa/acoramidis) | BBIO |  | completed, approved | "Based on the positive results from ATTRibute-CM, BridgeBio filed a new drug application (NDA) to the FDA, which has been accepted with a PDUFA action date of November 29, 2024, and the late cycle meeting with the FDA has been completed." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000095017024124576/bbio-ex99_1.htm)) |
| November 12, 2024 | [AUCATZYL (obecabtagene autoleucel) PDUFA date](https://sec-api.dev/pdufa/obecabtagene-autoleucel) | AUTL |  | completed, approved | "Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates November 12, 2024 at 7:00 AM EST AUCATZYL® (obecabtagene autoleucel) approved by US FDA on November 8, ahead of target PDUFA date of November 16" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730463/000173046324000132/autlex-991pr121124.htm)) |
| November 4, 2024 | [Emrosi (DFD-29) PDUFA date](https://sec-api.dev/pdufa/dfd-29) | FBIO |  | completed, approved | "In March 2024, the FDA accepted the NDA for DFD-29 and set a PDUFA goal date of November 4, 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1429260/000155837024015740/fbio-20240930x10q.htm)) |
| September 18, 2024 | [NEREUSTM (tradipitant) PDUFA date](https://sec-api.dev/pdufa/tradipitant) | VNDA | symptoms of gastroparesis to a final decision prior | completed, complete response letter | "In December 2023, the FDA accepted our NDA for NEREUSTM in gastroparesis for filing and set a PDUFA target action date of September 18, 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm)) |
| July 27, 2024 | [ZUNVEYL (benzgalantamine) PDUFA date](https://sec-api.dev/pdufa/benzgalantamine) | ACOG |  | completed, approved | "On December 7, 2023, the Company announced that the FDA accepted the Company's new drug application NDA for ZUNVEYL formerly ALPHA-1062 and has granted a PDUFA goal date of July 27, 2024." ([SEC registration statement (S-1)](https://www.sec.gov/Archives/edgar/data/1655923/000121390024114064/ea0217603-04.htm)) |
| April 23, 2024 | [ANKTIVA (inbakicept) PDUFA date](https://sec-api.dev/pdufa/inbakicept) | IBRX |  | completed, approved | "Although such designations may not lead to a faster development process or regulatory review and may not increase the likelihood that a product candidate will receive approval, N-803 (Anktiva), our lead biologic commercial product candidate, has received Breakthrough Therapy and Fast Track designations and is currently under review by the U.S. Food and Drug Administration (the FDA) for treatment in combination with bacillus Calmette-Guérin (BCG) of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without Ta or T1 disease and has a new user fee goal date (PDUFA date) of April 23, 2024." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1326110/000119312525165807/d941601d424b5.htm)) |
| February 26, 2024 | [Roluperidone PDUFA date](https://sec-api.dev/pdufa/roluperidone) | NERV |  | completed, complete response letter | "On May 8, 2023, we received confirmation from the FDA that the NDA for roluperidone has been assigned a standard review classification, and that the FDA has assigned a Prescription Drug User Fee Act ("PDUFA") goal date of February 26, 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1598646/000095017025108840/nerv-20250630.htm)) |
| February 24, 2024 | [Amtagvi® (lifileucel) PDUFA date](https://sec-api.dev/pdufa/lifileucel) | IOVA |  | completed, approved | "The FDA originally assigned November 25, 2023 as the target action date for a decision under PDUFA, however, the FDA then reassigned February 24, 2024 as the revised target action date before approving the BLA on February 16, 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1425205/000155837025010807/iova-20250630x10q.htm)) |
| November 23, 2023 | [Reproxalap PDUFA date](https://sec-api.dev/pdufa/reproxalap) | ALDX |  | completed, complete response letter | "In February 2023, the FDA accepted the Reproxalap NDA for filing and set a PDUFA date of November 23, 2023." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1341235/000095017025071602/aldx-20250331.htm)) |
| August 29, 2023 | [MVASI® (bevacizumab) PDUFA date](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | completed, complete response letter | "We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA on August 30, 2022, and in October 2022, we received confirmation from the FDA that our BLA had been accepted for filing with a goal date of August 29, 2023 for a review decision by the FDA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1649989/000155837025001022/otlk-20241231x10q.htm)) |
| July 28, 2023 | [LYMPHIR (lymphir) PDUFA date](https://sec-api.dev/pdufa/lymphir) | CTOR |  | completed, complete response letter | "In December 2022, a Biologics License Application ("BLA") for LYMPHIR was accepted for filing with the FDA and a PDUFA goal date was set for July 28, 2023." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1851484/000121390024113150/ea0225372-10k_citius.htm)) |

## Stock reaction

| Target date | Drug | Ticker | Outcome | 1-day move | 5-day move |
| --- | --- | --- | --- | --- | --- |
| November 14, 2026 | Ivonescimab | SMMT | CRL | n/a | n/a |
| October 26, 2026 | HIBSAGO (bepirovirsen) | GSK | approved | n/a | n/a |
| October 24, 2026 | Joenja® (leniolisib) | PHAR | approved | n/a | n/a |
| September 30, 2026 | ISEMBYLD (apitegromab) | SRRK | approved | n/a | n/a |
| September 26, 2026 | ATEBRIOZ® (zilurgisertib) | MIRM | approved | n/a | n/a |
| September 22, 2026 | ZANVASTRO™ (zilganersen) | IONS | approved | n/a | n/a |
| August 25, 2026 | Ziihera® (zanidatamab) | JAZZ | approved | n/a | n/a |
| August 2, 2026 | Opdivo® (nivolumab) | REPL | approved | n/a | n/a |
| Aug 2026 | MIMRYLO™ (rusfertide) | PTGX | approved | n/a | n/a |
| July 26, 2026 | Furosemide | MNKD | approved | n/a | n/a |
| July 17, 2026 | Revtorpyk (gedatolisib) | FTH | approved | n/a | n/a |
| July 11, 2026 | TAXOL® (paclitaxel) | CORT | approved | n/a | n/a |
| Q3 2026 | LISRAYA™ (brepocitinib) | ROIV | approved | n/a | n/a |
| Q3 2026 | ORZEYFUL (oveporexton) | TAK | approved | n/a | n/a |
| Q3 2026 | MIMRYLO™ (rusfertide) | TAK | approved | n/a | n/a |
| June 30, 2026 | TRYNGOLZA (olezarsen) | IONS | approved | n/a | n/a |
| June 30, 2026 | Lumvoa™ (veligrotug) | VRDN | approved | n/a | n/a |
| June 29, 2026 | ZORYVE (roflumilast) | ARQT | approved | n/a | n/a |
| June 26, 2026 | Lumvoa™ (veligrotug) | VRDN | approved | n/a | n/a |
| June 19, 2026 | WELIREG® (belzutifan) | MRK | approved | n/a | n/a |
| June 18, 2026 | Tebipenem | SPRO | approved | n/a | n/a |
| June 5, 2026 | IBRANCE® (palbociclib) | ARVN | approved | n/a | n/a |
| June 5, 2026 | VEPPANU (vepdegestrant) | ARVN | approved | n/a | n/a |
| May 31, 2026 | Indegene | CING | CRL | n/a | n/a |
| May 29, 2026 | Afrezza (afrezza) | MNKD | approved | n/a | n/a |
| April 30, 2026 | AUVELITY (dextromethorphan-bupropion) | AXSM | approved | n/a | n/a |
| April 28, 2026 | IDVYNSO (doravirine-islatravir) | MRK | approved | n/a | n/a |
| April 23, 2026 | GTX-104 | GRCE | CRL | n/a | n/a |
| April 13, 2026 | FILSPARI (sparsentan) | TVTX | approved | n/a | n/a |
| April 10, 2026 | Opdivo® (nivolumab) | REPL | CRL | n/a | n/a |
| April 10, 2026 | Vusolimogene oderparepvec | REPL | CRL | n/a | n/a |
| April 5, 2026 | Tividenofusp alfa | DNLI | approved | n/a | n/a |
| April 3, 2026 | SPINRAZA (nusinersen) | BIIB | approved | n/a | n/a |
| March 31, 2026 | ZYCUBO (CUTX-101) | FBIO | approved | n/a | n/a |
| March 28, 2026 | KRESLADI (marnetegragene autotemcel) | RCKT | approved | n/a | n/a |
| March 20, 2026 | IMCIVREE® (setmelanotide) | RYTM | approved | n/a | n/a |
| March 16, 2026 | Reproxalap | ALDX | CRL | n/a | n/a |
| March 10, 2026 | Deramiocel | CAPR | CRL | n/a | n/a |
| February 28, 2026 | Dupixent (dupilumab) | REGN | approved | n/a | n/a |
| February 25, 2026 | DESMODA (desmopressin) | ETON | approved | n/a | n/a |
| February 21, 2026 | BYSANTITM (milsaperidone) | VNDA | approved | n/a | n/a |
| February 8, 2026 | Clemidsogene lanparvovec | RGNX | CRL | n/a | n/a |
| January 31, 2026 | Joenja® (leniolisib) | PHAR | CRL | n/a | n/a |
| January 31, 2026 | Anaphylm™ (dibutepinephrine) | AQST | CRL | n/a | n/a |
| January 14, 2026 | ZYCUBO (CUTX-101) | FBIO | approved | n/a | n/a |
| January 10, 2026 | Tab-cel (tabelecleucel) | ATRA | CRL | n/a | n/a |
| December 31, 2025 | MVASI® (bevacizumab) | OTLK | CRL | n/a | n/a |
| December 30, 2025 | Corcept | CORT | CRL | n/a | n/a |
| December 30, 2025 | NEREUSTM (tradipitant) | VNDA | approved | n/a | n/a |
| December 28, 2025 | Tolebrutinib | SNY | CRL | n/a | n/a |
| December 26, 2025 | MYQORZO® (aficamten) | CYTK | approved | n/a | n/a |
| December 26, 2025 | YARTEMLEA® (narsoplimab) | OMER | approved | n/a | n/a |
| December 13, 2025 | CARDAMYST (etripamil) | MIST | approved | n/a | n/a |
| December 12, 2025 | ORLADEYO® (berotralstat) | BCRX | approved | n/a | n/a |
| November 30, 2025 | TEPKINLY (epcoritamab) | GMAB | approved | n/a | n/a |
| November 30, 2025 | KOMZIFTI (ziftomenib) | KURA | approved | n/a | n/a |
| November 18, 2025 | REDEMPLO (plozasiran) | ARWR | approved | n/a | n/a |
| October 25, 2025 | Revuforj® (revumenib) | SNDX | approved | n/a | n/a |
| October 13, 2025 | ZORYVE (roflumilast) | ARQT | approved | n/a | n/a |
| Q4 2025 | Levosimendan | TNXP | approved | n/a | n/a |
| September 30, 2025 | ZYCUBO (CUTX-101) | FBIO | CRL | n/a | n/a |
| September 22, 2025 | ISEMBYLD (apitegromab) | SRRK | CRL | n/a | n/a |
| September 22, 2025 | SPINRAZA (nusinersen) | BIIB | CRL | n/a | n/a |
| September 19, 2025 | JAKAFI (ruxolitinib) | INCY | approved | n/a | n/a |
| late 2025 | Oxylanthanum | UNCY | CRL | n/a | n/a |
| August 31, 2025 | Deramiocel | CAPR | CRL | n/a | n/a |
| August 29, 2025 | Wayrilz (rilzabrutinib) | SNY | approved | n/a | n/a |
| August 28, 2025 | FILSPARI (sparsentan) | TVTX | approved | n/a | n/a |
| August 27, 2025 | MVASI® (bevacizumab) | OTLK | CRL | n/a | n/a |
| August 27, 2025 | Zopapogene imadenovec | PGEN | approved | n/a | n/a |
| August 21, 2025 | DAWNZERA™ (donidalorsen) | IONS | approved | n/a | n/a |
| August 19, 2025 | Vatiquinone | PTCT | CRL | n/a | n/a |
| August 18, 2025 | FAYUVI (rebisufligene etisparvovec) | RARE | CRL | n/a | n/a |
| August 15, 2025 | Levosimendan | TNXP | approved | n/a | n/a |
| August 12, 2025 | BRINSUPRI® (brensocatib) | INSM | approved | n/a | n/a |
| August 8, 2025 | LNZ100 | LENZ | approved | n/a | n/a |
| Aug 2025 | Eylea® (eylea) | REGN | CRL | n/a | n/a |
| July 30, 2025 | Ordspono™ (odronextamab) | REGN | CRL | n/a | n/a |
| July 29, 2025 | Sephience™ (sepiapterin) | PTCT | approved | n/a | n/a |
| July 22, 2025 | Opdivo® (nivolumab) | REPL | CRL | n/a | n/a |
| June 30, 2025 | AVMAPKI (avutometinib) | VSTM | approved | n/a | n/a |
| June 28, 2025 | Oxylanthanum | UNCY | CRL | n/a | n/a |
| June 23, 2025 | IBTROZI (taletrectinib) | NUVB | approved | n/a | n/a |
| June 20, 2025 | Dupixent (dupilumab) | REGN | approved | n/a | n/a |
| June 19, 2025 | Yeztugo® (lenacapavir) | GILD | approved | n/a | n/a |
| June 13, 2025 | ZUSDURI (mitomycin) | URGN | approved | n/a | n/a |
| May 24, 2025 | YUTREPIA (treprostinil) | LQDA | approved | n/a | n/a |
| May 22, 2025 | ZORYVE (roflumilast) | ARQT | approved | n/a | n/a |
| April 29, 2025 | Prademagene | ABEO | approved | n/a | n/a |
| April 26, 2025 | TLX101 | TLX | CRL | n/a | n/a |
| April 20, 2025 | Eylea® (eylea) | REGN | CRL | n/a | n/a |
| April 18, 2025 | Dupixent (dupilumab) | REGN | approved | n/a | n/a |
| April 10, 2025 | VYVGART (efgartigimod) | ARGX | approved | n/a | n/a |
| April 3, 2025 | CABOMETYX® (cabozantinib) | EXEL | approved | n/a | n/a |
| April 2, 2025 | Reproxalap | ALDX | CRL | n/a | n/a |
| March 28, 2025 | CTEXLI® (chenodiol) | MIRM | approved | n/a | n/a |
| March 27, 2025 | CARDAMYST (etripamil) | MIST | CRL | n/a | n/a |
| March 24, 2025 | TLX007 | TLX | approved | n/a | n/a |
| March 23, 2025 | AMVUTTRA® (vutrisiran) | ALNY | approved | n/a | n/a |
| January 15, 2025 | Tab-cel (tabelecleucel) | ATRA | CRL | n/a | n/a |
| January 7, 2025 | Ryoncil (ryoncil) | MESO | approved | n/a | n/a |
| December 28, 2024 | UNLOXCYT (cosibelimab) | FBIO | approved | n/a | n/a |
| December 26, 2024 | Revuforj® (revumenib) | SNDX | approved | n/a | n/a |
| November 29, 2024 | Attruby (acoramidis) | BBIO | approved | n/a | n/a |
| November 12, 2024 | AUCATZYL (obecabtagene autoleucel) | AUTL | approved | n/a | n/a |
| November 4, 2024 | Emrosi (DFD-29) | FBIO | approved | n/a | n/a |
| September 18, 2024 | NEREUSTM (tradipitant) | VNDA | CRL | n/a | n/a |
| July 27, 2024 | ZUNVEYL (benzgalantamine) | ACOG | approved | n/a | n/a |
| April 23, 2024 | ANKTIVA (inbakicept) | IBRX | approved | n/a | n/a |
| February 26, 2024 | Roluperidone | NERV | CRL | n/a | n/a |
| February 24, 2024 | Amtagvi® (lifileucel) | IOVA | approved | n/a | n/a |
| November 23, 2023 | Reproxalap | ALDX | CRL | n/a | n/a |
| August 29, 2023 | MVASI® (bevacizumab) | OTLK | CRL | n/a | n/a |
| July 28, 2023 | LYMPHIR (lymphir) | CTOR | CRL | n/a | n/a |

Moves are shown only where a licensable price source is available; n/a means not measured.

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA outcomes: approvals and CRLs on past target dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa-outcomes

```bibtex
@misc{secapidev_pdufa_outcomes_20261116,
  title        = {PDUFA outcomes: approvals and CRLs on past target dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa-outcomes}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_outcomes_20261116","title":"PDUFA outcomes: approvals and CRLs on past target dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa-outcomes","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
